A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder (MDD)

Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder (MDD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan; Forest Laboratories
  • Most Recent Events

    • 05 Aug 2016 Primary endpoint (Montgomery-Asberg Depression Rating Scale) has not been met, according to an Allergan and Richter joint media release.
    • 07 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016.
    • 07 Jun 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top